This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

July 10, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

BI 1015550

Tablet formulation

DRUG

Placebo

Tablet formulation

Trial Locations (13)

1200

Brussels - UNIV Saint-Luc, Brussels

20520

TYKS, Keuhkosairauksien klinikka, Turku, Turku

30625

Fraunhofer ITEM, Hanover

69126

Universitätsklinikum Heidelberg, Heidelberg

5000 C

Odense University Hospital, Odense

00290

HYKS Keuhkosairauksien tutkimusyksikkö, Helsinki

00168

Policlinico Gemelli, Roma

3435 CM

St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein

3015 CE

Erasmus Medisch Centrum, Rotterdam

08036

Hospital Clínic de Barcelona, Barcelona

08907

Hospital de Bellvitge, L'Hospitalet de Llobregat

SW3 6NP

Royal Brompton Hospital, London

SO16 6YD

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03422068 - This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. | Biotech Hunter | Biotech Hunter